Telix Pharmaceuticals Limited TLX
Set alert
9.08 USD +0.03 +0.33%
As of Nov 3, 10:53 AM ET
9.01 Day range 9.09
6.28 52-week range 13.11
- YTD
- +21.23%
- 1 year
- -12.61%
- Open
- 9.05
- Prev close
- 9.05
- Mkt cap
- 3.08B
- Vol
- 55.72K
- Avg vol
- 323.44K
- EPS
- 0.10
- P/E
- 90.80
- Div yield
- 0.00%
More statistics
- Low
- 9.01
- High
- 9.09
- Forward P/E
- -338.83
- Beta
- 0.63
- Short ratio
- 0.76
- Inst. own
- 1.02%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 19, 2027
- 50-d avg
- 11.05
- 200-d avg
- 9.90
- 1y target
- 20.45
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 20.45 +125.2% upside
Now 9.08
- Target (low)
- 17.91
- Target (mean)
- 20.45
- Target (high)
- 21.94
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.086 | 0.086 – 0.086 | 0.00 | 0.0% | 329.36M | +3.6% | 1 |
| Next quarter | 0.086 | 0.086 – 0.086 | 0.00 | 0.0% | 318.75M | +2.9% | 1 |
| Current year | 0.1614 | 0.026 – 0.429 | -0.0299 | +639.8% | 1.39B | +16.2% | 5 |
| Next year | -0.038 | -0.051 – -0.025 | 0.1614 | -123.5% | 1.57B | +13.1% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 25, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 23, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 14, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 2, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 20, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jul 7, 2026 | Citigroup | Maintained | Buy | Buy |
| Jul 7, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 6, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Apr 13, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Apr 13, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 7, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Apr 7, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 24, 2026 | Citigroup | Maintained | Buy | Buy |
| Jan 21, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 22, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 23, 2025 | UBS | Maintained | Buy | Buy |
| Sep 18, 2025 | Citigroup | Initiated | — | Buy |
| Sep 10, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 28, 2025 | JP Morgan | Downgrade | Overweight | Neutral |
| Aug 28, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Jul 3, 2025 | HC Wainwright & Co. | Initiated | — | Buy |
| Jun 12, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 5, 2025 | Wedbush | Initiated | — | Outperform |
| Jan 27, 2025 | UBS | Maintained | Buy | Buy |
| Nov 15, 2024 | UBS | Initiated | — | Buy |